Aktienanalyse zu GeoVax Labs Inc (GOVX)GOVXGeoVax Labs Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GeoVax Labs Inc (GOVX) is currently not a good buy due to its extremely low RSI of 16.12, indicating it is oversold, and a staggering year-to-date change of -96.95%. While analysts have set a price target of $10, the stock is currently trading at $0.16, suggesting a potential upside, but the risks are significant given the company's recent financial performance and operational challenges.